WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.
"When new effective medicines emerge to safely treat serious and widespread diseases, it is vital to ensure that everyone who needs them can obtain them," said WHO Director-General, Dr Margaret Chan. "Placing them on the WHO Essential Medicines List is a first step in that direction."
Increasingly, governments and institutions around the world are using the WHO list to guide the development of their own essential medicines lists, because they know that every medicine listed has been vetted for efficacy, safety and quality, and that there has been a comparative cost-effectiveness evaluation with other alternatives in the same class of medicines.
The list is updated every two years by an Expert Committee, made up of recognized specialists from academia, research and the medical and pharmaceutical professions. This year, the Committee underscored the urgent need to take action to promote equitable access and use of several new highly effective medicines, some of which are currently too costly even for high-income countries.
New medicines to treat Hepatitis C
These included new medicines to treat hepatitis C, which affects about 150 million people globally, killing approximately half a million people each year, when chronic infection develops into liver cirrhosis or liver cancer. The disease is present in high- and lower-income countries alike, with higher concentrations in several middle- and low-income countries.
Until recently, treatment for the disease presented minimal therapeutic benefits and serious side effects. Five new medicines - direct acting oral antivirals - have recently come on the market transforming chronic hepatitis C from a barely manageable to a curable condition, the new medicines have few side effects and high tolerance in patients. All 5 products, including sofosbuvir and daclatasvir, were included in the List. But high prices currently make them unaffordable and thus inaccessible to most people who need them.
"Treatments for hepatitis C are evolving rapidly, with several new, highly effective and safe medicines on the market and many in the development pipeline," said Dr Marie-Paule Kieny, WHO Assistant Director-General for Health Systems and Innovation. "While some efforts have been made to reduce their price for low-income countries, without uniform strategies to make these medicines more affordable globally the potential for public health gains will be reduced considerably."
Cancers figure among the leading causes of illness and death worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012. The number of new cases is expected to rise by about 70% over the next 2 decades. New breakthroughs have been made in cancer treatment in the last years, which prompted WHO to revise the full cancer segment of the Essential Medicines List this year: 52 products were reviewed and 30 treatments confirmed, with 16 new medicines included in the List.
"Some of these medicines produce relevant survival benefits for cancers with high incidence, such as trastuzumab for breast cancer," explained Dr Kees De Joncheere, WHO Director of Essential Medicines. "Other treatment regimens for rare cancers such as leukemia and lymphoma, which can cure up to 90% of patients, were added to set a global standard."
TB remains one of the world's most deadly infectious diseases. In 2013, 9 million people fell ill with TB and 1.5 million died from the disease. Over 95% of TB deaths occur in low- and middle-income countries. After about 45 years of scarce innovation for TB medicines, 5 new products were included in the EML. Four of these, including bedaquiline and delamanid, target multi-drug-resistant TB.
The Committee also recommended supporting off-label uses in cases where there is clear evidence of major health benefits, though no licensed indication, such as for many medicines for children.
"The Essential Medicines List includes medicines on the basis of safety and efficacy evidence, not on the basis of approved indications within national jurisdictions or availability of licensed alternatives," added Dr De Joncheere. "For example, when it reviewed the application to include ranibizumab, to treat severe eye diseases such as macular degeneration, the Committee looked at the evidence base and the price difference with bevacizumab - the medicine currently listed. The Committee agreed to maintain bevacizumab as the preferred medicine, rejecting the ranibizumab application. "
"It is important to understand that the Essential Medicines List is the starting block and not the finishing line," concluded Dr Kieny. "Its purpose is to provide guidance for the prioritization of medicines from a clinical and public health perspective.The hard work begins with efforts to ensure that those medicines are actually available to patients."
Childhood vaccinations save trillions in societal costs while preventing millions of illnesses and deaths